source
- Biogen pushing tau drug forward despite Alzheimer’s study failureOne of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
- FDA leadership gap deepens uncertainty for biotech as acting officials take chargeMarty Makary's resignation as FDA commissioner has left the agency without a permanent head. Kyle Diamantas is serving as the temporary leader, while three senior drug-review positions are filled b…